[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"beta-lactams\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:beta-lactams":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100630204","phase-4-a-study-to-compare-the-efficacy-and-safety-of-extended-and-intermittent-infusion-of-beta-lactams-in-critically-ill-paediatric-patients-100630204",false,"NCT07484633","A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","A Protocol of a Randomised, Two-arm Superiority Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","PEBBLE","Inclusion Criteria:\n\n* paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination;\n* who are receiving β-lactams including meropenem, piperacillin\u002Ftazobactam, cefepime and ceftriaxone;\n* who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration;\n* written consent of the parent or guardian is obtained.\n\nExclusion Criteria:\n\n* palliative care patients;\n* patients participating in other drug trials;\n* patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate \\[eGFR\\]\\\u003C50 mL\u002Fmin\u002F1.73m2 for meropenem, cefepime, and piperacillin\u002Ftazobactam; eGFR\\\u003C10 mL\u002Fmin\u002F1.73m2 for ceftriaxone);\n* patients undergoing plasmapheresis (TPE);\n* patients undergoing extracorporeal therapy (continuous kidney replacement therapy \\[CKRT\\] or extracorporeal membrane oxygenation \\[ECMO\\]);\n* β-lactam allergy;\n* patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours;\n* pregnancy.","ALL","0 Hours","17 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.\n\nThe main question it aims to answer is:\n\nIs the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.\n\nParticipants will:\n\n* be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion.\n* be examined to make sure their blood drug levels are correct. This will require two blood tests.\n* be treated according to routine care and have examinations and blood tests performed.",[28,29,30,31,32],"Infection","Sepsis","NICU","PICU","Beta Lactams","NOT_YET_RECRUITING","2026-04-07",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":22},"2026-04",{"date":41,"type":22},"2028-04",{"name":43,"class":44},"Semmelweis University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100608395","prevalence-of-carriage-of-extended-spectrum-beta-lactamase-esbl-producing-enterobacteria-in-preterm-premature-rupture-of-membranes--a-french-multicenter-cohort-study-100608395","NCT07200999","Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study","Inclusion Criteria :\n\n* Pregnant women aged over 18 years\n* Diagnosed with premature rupture of membranes before term (between 23 weeks + 0 days and 36 weeks + 6 days of gestation)\n* Managed in one of the participating maternity hospitals\n\nExclusion Criteria :\n\n* No available microbiological sample\n* Minors or women under legal guardianship (curatorship, tutelage, or judicial protection)\n* Women who refuse the use of their clinical data for research purposes at admission or within one month after receiving the information document","FEMALE","18 Years",{"count":54,"type":22},250,"OBSERVATIONAL","This study looks at how common certain antibiotic-resistant bacteria (called extended-spectrum beta-lactamase-producing Enterobacteriaceae, or E-BLSE) are in pregnant women who experience premature breaking of their water before full term. The goal is to understand how often these bacteria are found, how long they stay, and what factors increase the risk of carrying them. This information will help doctors choose the best antibiotics to protect both the mother and baby from infections during and after pregnancy. The study follows women from the time of their membrane rupture until delivery, collecting samples to track the bacteria over time.",[58,59,60,61,62,63,64],"Premature Rupture of Membranes","Enterobacteriaceae","Beta-Lactams","Drug Resistance, Bacterial","Antibiotic Prophylaxis","Pregnancy","Intrauterine Infection","2025-09-23",{"date":67,"type":37},"2025-10-01",{"date":67,"type":22},{"date":70,"type":22},"2026-12-15",{"name":72,"class":44},"Centre Hospitalier de Saint-Denis",1]